MedTrace Logo

Effects Of Sitaxsentan On Proteinuria, 24-Hour Blood Pressure, And Arterial Stiffness In Chronic Kidney Disease Subjects

NCT00810732 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 27

Last updated 2023-07-06

Study results available
· View outcomes & findings →

Summary

This study is being conducted to evaluate sitaxsentan dosing in subjects with chronic kidney disease.

Conditions

Interventions

DRUG

Open

Sitaxsentan sodium 100 mg orally administered once daily (double blind arm)

DRUG

Nifedipine

Nifedipine = 30 mg extended release tablets, orally administered once daily (open label arm)

DRUG

Placebo

Placebo for sitaxsentan, orally administered once daily (double blind arm)

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-05-09
Primary Completion
2009-03-06
Completion
2009-03-06

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00810732 on ClinicalTrials.gov